Why Corcept Therapeutics now faces a bigger execution test after Lifyorli’s ROSELLA success
Corcept Therapeutics’ Lifyorli showed strong survival benefit in ovarian cancer. Read what the ROSELLA data could change for clinicians and payers.
Corcept Therapeutics expands hypercortisolism evidence base with largest US resistant hypertension screening trial
Corcept’s MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients. Explore what this means for screening and treatment. Read more.
Can Corcept’s Lifyorli become a real new standard in platinum-resistant ovarian cancer after FDA approval?
Corcept’s Lifyorli won FDA approval in platinum-resistant ovarian cancer. Read what the survival data could change for clinicians, rivals, and regulators.